International Journal of Hematology and Oncology 2021, Vol 31, Num 3 Page(s): 180-189
Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?

Fatma Bugdayci BASAL1, Ferit ASLAN1, Guliz ZENGIN1, Irem BILGETEKIN1, Berna OKSUZOGLU1, Umut DEMIRCI1

Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, TURKEY

Keywords: Locally advanced non-small cell lung cancer, Consolidation chemotherapy, Concurrent chemoradiotherapy, Overall survival, Progression-free survival
The role of consolidation chemotherapy is being investigated due to inconclusive outcomes, ascribed to high rates of recurrence and mortality with standard concurrent chemoradiotherapy (CRT) in patients with unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). We evaluated the impact of consolidation chemotherapy on the survival of patients with LA-NSCLC at our single medical centre. In total, 136 patients with unresected LA-NSCLC were evaluated to identify and compare the factors influencing survival rates. The median overall survival (OS) was 27 and 23.6 months and median progression-free survival (PFS) was 12.3 and 12.8 months in the CRT and consolidation treatment groups (p= 0.840 and 0.808), respectively. Consolidation chemotherapy after concurrent CRT experiences has neither OS nor PFS survival benefit, compared with concurrent CRT alone. Thus, our study did not support favourable consolidation chemotherapy in patients with LA-NSCLC.